ALSO NOTED: Canada nixes Lilly's Parkinson's drug; Company looks to snap up ex-Pfizer workers;

> Eli Lilly's Permax will be persona non grata in Canada as of August 30. After studies showed the Parkinson's treatment can cause serious heart-valve damage, Lilly in March voluntarily pulled Permax from the U.S. market. Now, Health Canada is ordering the company to stop selling the drug there. Report

> Health Canada also becomes the latest regulator to announce it's reviewing safety data on Prexige, the Novartis Cox-2 inhibitor that Australia withdrew from the market earlier this week. Release

> Laid-off Pfizer staffers may have reason to hope: A pharmaceutical services company is opening an Ann Arbor location, and it's eyeing ex-Pfizer types. Report

> The FDA wants more time to review Endo Pharmaceuticals' supplemental new drug app for the pain med Frova. Endo had applied to expand Frova's label to short-term prevention of menstrual migraine. Report

And Finally... Lyrica isn't making hay only for Pfizer. The $1.2 billion nerve-pain and epilepsy med is bestowing plenty of moolah onto its alma mater, Northwestern University, where chemist Richard Silverman laid the groundwork necessary for its development. Blog

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.